Pfizer repels Covid-19 sales tumble to raise 2026 guidance
Pfizer has upgraded the bottom-end of its full-year (FY) revenue outlook by $500m as performance from the drugmaker’s lead products…
04 Aug 2026
Supernus and Indivior merge to create scaled, CNS-focused entity
Supernus Pharmaceuticals and Indivior Pharmaceuticals are joining forces to create a diversified and scaled biopharmaceutical company focused on the central nervous system (CNS). Through this all-stock merger, which is expected…
04 Aug 2026
FDA grants breakthrough therapy designation to Lilly’s olomorasib
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Eli Lilly and Company’s (Lilly) olomorasib as a potential treatment for adults with advanced pancreatic cancer who…
04 Aug 2026
Curium to acquire Lantheus in all-cash deal worth up to $8bn
CapVest Partners-backed Curium has agreed to buy rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn. The deal will take the Nasdaq-listed Lantheus private. Under…
03 Aug 2026
Amgen contends with data breach, exposing patient information
Amgen has been hit with a data breach impacting its third-party operated cloud-based systems – an event which the company says has compromised both company-owned data and private patient health…
03 Aug 2026
AstraZeneca shares slump after $400bn BMS merger rumours
Shares in AstraZeneca dropped by nearly 3% at market open after a report that the drugmaker is in talks with oncology rival Bristol Myers Squibb (BMS) regarding a mega-merger deal.…
03 Aug 2026
IMPACT Therapeutics grants Pharmanovia exclusive $488m rights to senaparib
China-based IMPACT Therapeutics and Pharmanovia have entered an exclusive licensing deal worth up to €423.5m ($488.3m), giving Pharmanovia rights to manufacture, develop, and commercialise senaparib in 66 countries. The agreement…